News
CMPX
1.010
-6.48%
-0.070
Weekly Report: what happened at CMPX last week (0708-0712)?
Weekly Report · 9h ago
Weekly Report: what happened at CMPX last week (0701-0705)?
Weekly Report · 07/08 10:45
Weekly Report: what happened at CMPX last week (0624-0628)?
Weekly Report · 07/01 10:45
Weekly Report: what happened at CMPX last week (0617-0621)?
Weekly Report · 06/24 10:51
Compass Therapeutics: Pointing Right At Some Tough Cancers
Seeking Alpha · 06/20 07:14
Weekly Report: what happened at CMPX last week (0610-0614)?
Weekly Report · 06/17 10:44
12 Health Care Stocks Moving In Monday's After-Market Session
Entero Therapeutics (NASDAQ:ENTO) stock rose 10.2% to $2.6 during Monday's after-market session. LifeMD stock rose 5.81% in the same period. Losers Vicarious Surgical (NYSE:RBOT) and ProKidney stock fell 15.6% during the session.
Benzinga · 06/10 20:31
Weekly Report: what happened at CMPX last week (0603-0607)?
Weekly Report · 06/10 10:46
Compass Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 06/03 11:10
HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target
Benzinga · 06/03 11:00
Weekly Report: what happened at CMPX last week (0527-0531)?
Weekly Report · 06/03 10:48
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Compass Therapeutics (CMPX) and Kymera Therapeutics (KYMR)
TipRanks · 06/03 10:30
Compass Therapeutics Announces CEO Transition and New Leadership
TipRanks · 05/28 22:07
Compass Therapeutics names Thomas Schuetz as CEO
Healthcare Compass Therapeutics names Thomas Schuetz as CEO May 28, 2024. The company's stock is up 1.7% to $7.50. Compass TherAPEutics, Inc. (CMPX) has been named as a potential takeover target for a number of companies.
Seeking Alpha · 05/28 20:20
Compass Therapeutics Appoints Thomas Schuetz As President And CEO, Effective May 28, 2024; Vered Bisker-Leib Has Stepped Down
Benzinga · 05/28 20:13
*Compass Therapeutics: Bisker-Leib Will Continue to Be Available as Senior Consultant for Next 15 Mos >CMPX
Dow Jones · 05/28 20:11
*Compass Therapeutics: Vered Bisker-Leib Stepped Down as CEO, Board Member
Dow Jones · 05/28 20:11
COMPASS THERAPEUTICS INC.: VERED BISKER-LEIB, STEPPED DOWN AS CEO AND AS A MEMBER OF BOARD OF DIRECTORS OF COMPANY
Reuters · 05/28 20:10
*Compass Therapeutics Announces CEO Transition >CMPX
Dow Jones · 05/28 20:10
*Compass Therapeutics Appoints Thomas Schuetz, M.D., Ph.D. as Pres and CEO, Effective May 28 >CMPX
Dow Jones · 05/28 20:10
More
Webull provides a variety of real-time CMPX stock news. You can receive the latest news about Compass Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CMPX
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, CTX-009, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor and its ligand PD-L1, two validated immune-oncology targets.